Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Chiome Bioscience's Median PS Value or its related term are showing as below:
TSE:4583'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27 Med: 0.44 Max: 2.71
Current: 0.59
During the past 13 years, the highest Price to Median PS Value of Chiome Bioscience was 2.71. The lowest was 0.27. And the median was 0.44.
TSE:4583's Price-to-Median-PS-Value is ranked better than 53.93% of 280
companies
in the Biotechnology industry
Industry Median: 0.625
vs TSE:4583: 0.59
Chiome Bioscience (TSE:4583) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Chiome Bioscience's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
97.00
/
164.09
=
0.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiome Bioscience Median PS Value Related Terms
Chiome Bioscience Median PS Value Historical Data
* Premium members only.
The historical data trend for Chiome Bioscience's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4583 vs VRTX, REGN, MRNA: Median PS Value Comparison
For the Biotechnology subindustry, Chiome Bioscience's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiome Bioscience Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Chiome Bioscience's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 18.5371.
Chiome Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円8.852.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiome Bioscience (TSE:4583) has a Median PS Value of 円164.09 as of Sep. 09, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Chiome Bioscience and its competitors. According to the industry distribution chart, Chiome Bioscience ranks #129 out of 280 companies in the Biotechnology industry, placing it in the top 46.1%.
Is Chiome Bioscience's Median PS Value too high?
Chiome Bioscience's current Median PS Value is 円164.09. Based on the distribution chart, Chiome Bioscience ranks #129 out of 280 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chiome Bioscience has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chiome Bioscience ranks #129 out of 280 companies for Median PS Value. This puts Chiome Bioscience in the upper half of its industry. The industry median Median PS Value is 0.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 280 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Chiome Bioscience and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chiome Bioscience's current Median PS Value is 円164.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Modestly Overvalued. The stock's GF Value™ is 円87.77, compared to a current price of 円97.00 — trading 10.5% above its estimated fair value. The current Median PS Value is 円164.09. Chiome Bioscience's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Median PS Value is 円164.09 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chiome Bioscience (TSE:4583) Overvalued in 2026?
Based on GuruFocus' analysis, Chiome Bioscience stock appears to be overvalued.
The current stock price of 円97.00 is trading 10.5% above its estimated GF Value™ of 円87.77.
GuruFocus considers Chiome Bioscience to be Modestly Overvalued.
Key valuation signals for TSE:4583:
Median PS Value: 円164.09
GF Value™: 円87.77 vs. price of 円97.00 (10.5% above fair value)
No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
50GF Score
Get the complete analysis for TSE:4583
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4583 has been successfully added to your 
